Premium
Shedding light on IRIS: from Pathophysiology to Treatment of Cryptococcal Meningitis and Immune Reconstitution Inflammatory Syndrome in HIV‐Infected Individuals
Author(s) -
Balasko A,
Keynan Y
Publication year - 2019
Publication title -
hiv medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.53
H-Index - 79
eISSN - 1468-1293
pISSN - 1464-2662
DOI - 10.1111/hiv.12676
Subject(s) - immune reconstitution inflammatory syndrome , medicine , immune system , immunology , immune dysregulation , antiretroviral therapy , human immunodeficiency virus (hiv) , viral load
Objectives The aim of this work was to review current treatment options and propose alternatives for immune reconstitution inflammatory syndrome ( IRIS ) in HIV ‐infected individuals with cryptococcal meningitis ( CM ) (termed ‘HIV‐CM IRIS’). As a consequence of the immunocompromised state of these individuals, the initial immune response to CM is predominantly type 2 T helper (Th2) /Th17 rather than Th1, leading to inefficient fungal clearance at the time of antiretroviral initiation, and a subsequent overexaggeration of the Th1 response and life‐threatening IRIS development. Methods An article‐based and clinical trial‐based search was conducted to investigate HIV ‐ CM IRIS pathophysiology and current treatment practices. Results Guidelines for CM treatment, based on the Cryptococcal Optimal Antiretroviral Timing ( COAT ) trial, recommend delayed antiretroviral therapy ( ART ) following antifungal treatment. The approach aims to decrease fungal burden and allow immune balance restoration prior to ART initiation. If the initial immune balance is not restored, the fungal burden is not sufficiently reduced and there is a risk of developing IRIS post‐ ART , highlighted by a Th1 immune overcompensation, leading to increased mortality. The mainstay treatment for Th1‐biased IRIS is corticosteroids; however, this treatment has been shown to correlate with increased mortality and significant associated adverse events. We emphasize targeting a more specific Th1 mechanism via the tumour necrosis factor ( TNF )‐α cytokine antagonist thalidomide, as it is the only TNF ‐α antagonist currently approved for use in infectious disease settings and has been shown to decrease Th1 overreaction, restoring immune balance in HIV ‐ CM IRIS . Conclusions Although the side effects and limitations of thalidomide must be considered, it is currently being successfully used in infectious disease settings and warrants mainstream application as a therapeutic option for treatment of IRIS in HIV‐infected patients with CM.